Skip to main content

Table 3 Baseline characteristics of treatment groups

From: Effectiveness of a fortified drink in improving B vitamin biomarkers in older adults: a controlled intervention trial

Demographic variable Group P value
Placebo Active
  (n 40) (n 41)
Age (years) 65.2 (8.4) 64.7 (6.3) 0.784
Sex n male (female) 17 (23) 16 (25)
Weight (kg) 73.0 (63.4–84.0) 72.8 (63.3–84.2) 0.916
Height (m) 1.69 (0.09) 1.68 (0.08) 0.587
BMI (kg/m2) 25.5 (23.5–29.5) 25.4 (23.4–29.5) 0.860
Waist (cm) 92.70 (82.63–102.50) 89.75 (81.50–105.05) 0.702
Hip (cm) 104.28 (8.56) 104.42 (8.74) 0.944
Waist:hip 0.89 (0.09) 0.90 (0.10) 0.605
Systolic BP (mmHg) 130.9 (19.7) 127.6 (20.3) 0.469
Diastolic BP (mmHg) 76.2 (8.6) 74.6 (10.1) 0.321
Plasma total 25(OH)D (nmol/L) 62.5 (22.4) 59.3 (25.2) 0.539
Serum Homocysteine (µmol/L) 11.05 (9.68–12.75) 11.86 (10.29–15.05) 0.047
Serum folate (nmol/L) 18.0 (14.3–21.9) 15.5 (11.8–21.6) 0.123
Serum vitamin B12 (pmol/L) 336 (235–449) 310 (246–409) 0.357
Plasma PLP (vitamin B6; nmol/L) 61.7 (48.6–85.1) 59.4 (44.5–74.1) 0.487
Riboflavin (EGRac) 1.29 (1.24–1.35) 1.34 (1.25–1.43) 0.168
  1. Data presented as mean (SD) and median (IQR). P value of differences between treatment groups, p < 0.05 considered statistically significant. BP, blood pressure; EGRac, erythrocyte glutathione reductase activation coefficient; PLP, Pyridoxal 5′-phosphate